– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –

BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while preserving systolic function.

Late-Breaking Science Presentation:

Title: CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy

Presenter: Anjali Tiku Owens, M.D., Associate Professor of Medicine in the Division of Cardiology at the Perelman School of Medicine of the University of Pennsylvania

Date: Monday, August 31, 2026, 11:30 – 11:45 am CEST

Session: Transforming the heart: novel therapies for myocardial disease and heart failure

Location: Achgabat (Hall A3)

The presentation will be available on the Edgewise website after it is presented.

About CIRRUS-HCM

CIRRUS-HCM is a multi-part, open label trial of EDG-7500 in participants with obstructive and nonobstructive HCM at over 20 clinical sites in the U.S. Part A of the trial evaluated the safety and tolerability of a single oral dose of EDG-7500 in participants with obstructive HCM (oHCM). Parts B and C evaluated fixed doses of EDG-7500 over 28 days in oHCM and nonobstructive HCM (nHCM), respectively; the results can be found here. Part D is a 12-week study including participants with oHCM and nHCM designed to explore dose response and optimization, followed by an open-label extension; the results can be found here. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159.

About Hypertrophic Cardiomyopathy

HCM is the most common form of genetic heart disease, affecting approximately one in 500 people, and is associated with reduced quality of life and an elevated risk of heart failure, abnormal heart rhythms, and sudden cardiac death. Individuals with HCM can become extremely limited in their functional capacity and ability to perform the activities of daily living. Commonly experienced symptoms include breathlessness, irregular heartbeat, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood (diastolic dysfunction). There are two major forms of HCM: obstructive and nonobstructive. Despite advancements in treatment options for some patients with HCM, there remains a significant unmet need for additional therapeutic approaches for patients.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading biopharmaceutical company focused on developing innovative therapies for serious cardiovascular and cardiometabolic diseases. Leveraging its expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy and heart failure. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-upcoming-late-breaking-science-presentation-at-the-european-society-of-cardiology-esc-congress-2026-302857842.html

SOURCE Edgewise Therapeutics